Osteoporosis Therapeutics

Osteoporosis Therapeutics

Global Osteoporosis Therapeutics Market to Reach $14.2 Billion by 2026

Osteoporosis constitutes a bone disorder characterized by a decreased level of bone mineral density (BMD), and/or reduced bone strength, and deterioration of bone architecture, resulting in increased risk of fractures. Afflicting more than 200 million people worldwide, the potentially life-threatening disease - osteoporosis poses a major clinical challenge to the medical world. Osteoporosis therapeutics are mainly targeted at reducing the risk of fractures, and are categorized into two main drug categories, named antiresorptive or anabolic. Antiresorptive drugs reduce bone resorption and include mainly bisphosphonates, estrogens, estrogen agonist/ antagonists [EAAs], calcitonin, and denosumab. Anabolic drugs work by increasing bone formation and include teriparatide. The osteoporosis drugs are approved by the FDA for treating Post-Menopausal Osteoporosis (PMO); Osteoporosis in men, and also GIO.

The osteoporosis therapeutics market is still largely untapped, with only about a third of osteoporosis patients being diagnosed and treated for the condition, which opens up lucrative growth opportunities for pharmaceutical companies. Factors such as aging population, growing awareness of osteoporosis, continuing new product introductions, and expansion of bone densitometry scanning, are expected to steer growth in the market. Amid the COVID-19 crisis, the global market for Osteoporosis Therapeutics estimated at US$12.7 Billion in the year 2022, is projected to reach a revised size of US$14.2 Billion by 2026, registering a compounded annual growth rate (CAGR) of 2.9% over the analysis period. United States represents the largest regional market for Osteoporosis Therapeutics, accounting for an estimated 40.8% share of the global total. The market is projected to reach US$5.5 Billion by 2026. China is expected to spearhead growth and emerge as the fastest growing regional market with a CAGR of 5.4% over the analysis period.

The US and the Europe are the major markets for Osteoporosis therapeutics. The key factors driving the US and European osteoporosis drugs markets are the existence of well-established healthcare & medical infrastructure, favorable R&D policies towards osteoporosis drug applications, and significant investments in healthcare activities. On the other hand, developing economies are witnessing significant government and private investments in healthcare infrastructure development, driving the market for therapeutic medicines. Healthcare spending in Asia-Pacific is forecast to register a notable expansion fueled by rising consumer income, public healthcare systems` initiatives and lifestyle changes. Despite the availability of a wide variety of treatment options, inadequate awareness of osteoporosis and lack of proper diagnosis equipment have been the major factors plaguing industry growth over the years.

Select Competitors (Total 53 Featured) -
  • Alergan Plc.
  • Amgen, Inc.
  • Chugai pharmaceutical
  • Daiichi Sankyo Co., Ltd.
  • Egalet Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.;
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
A Prelude to Osteoporosis
Growing Geriatric Population and Rising Incidence of Osteoporosis Drive the Global Osteoporosis Market
Developed Regions Dominate the Global Market, Developing to Witness Fastest Growth
Bisphosphonates - The Largest Category of Drugs for Treating Osteoporosis
Approved Drugs for Treatment of Osteoporosis
Select Recent Osteoporosis Drug Approvals
Osteoporosis Therapeutics – Global Key Competitors Percentage Market Share in 2022 (E)
Sales of Leading Osteoporosis Therapeutics: 2018
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Growing Incidence of Osteoporosis Augurs Well for Osteoporosis Therapeutics
Global Osteoporosis Prevalence by Country/Region (2012 & 2022P): Number of People with Osteoporosis in Millions for US, EU, Japan, China and India
% of Women Affected by Osteoporosis
Osteoporosis – Factsheet
Osteoporosis in Men
Rising Geriatric Population and the Associated Bone Health Issues to Drive Market Gains
Global Population of 65+ Individuals (In 000s) by Region for the Years 2015, 2020 & 2025
Rising Prevalence of Osteoporosis in Post-menopausal Women Propels Market Growth
Changing Lifestyle Impacting Bone Health
Recommended Daily Intake of Calcium and Vitamin D
Increasing Awareness Related to Osteoporosis Care
New Product Launches Foster Market Growth
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 2: World Historic Review for Osteoporosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 3: World 15-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
TABLE 4: World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 5: World Historic Review for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 6: World 15-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 7: World Recent Past, Current & Future Analysis for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 8: World Historic Review for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 9: World 15-Year Perspective for Parathyroid Hormone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 10: World Recent Past, Current & Future Analysis for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 11: World Historic Review for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 12: World 15-Year Perspective for Calcitonin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 13: World Recent Past, Current & Future Analysis for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 14: World Historic Review for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 15: World 15-Year Perspective for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 16: World Recent Past, Current & Future Analysis for Rank Ligand Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 17: World Historic Review for Rank Ligand Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 18: World 15-Year Perspective for Rank Ligand Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 19: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 20: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 21: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 22: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 23: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 24: World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 25: World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 26: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 27: World 15-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
TABLE 28: USA Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 29: USA Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 30: USA 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027
TABLE 31: USA Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 32: USA Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 33: USA 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027
CANADA
TABLE 34: Canada Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 35: Canada Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 36: Canada 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027
TABLE 37: Canada Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 38: Canada Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 39: Canada 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027
JAPAN
Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
TABLE 40: Japan Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 41: Japan Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 42: Japan 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027
TABLE 43: Japan Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 44: Japan Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 45: Japan 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027
CHINA
Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
TABLE 46: China Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 47: China Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 48: China 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027
TABLE 49: China Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 50: China Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 51: China 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027
EUROPE
Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
TABLE 52: Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 53: Europe Historic Review for Osteoporosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 54: Europe 15-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
TABLE 55: Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 56: Europe Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 57: Europe 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027
TABLE 58: Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 59: Europe Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 60: Europe 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027
FRANCE
Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
TABLE 61: France Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 62: France Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 63: France 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027
TABLE 64: France Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 65: France Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 66: France 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027
GERMANY
Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
TABLE 67: Germany Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 68: Germany Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 69: Germany 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027
TABLE 70: Germany Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 71: Germany Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 72: Germany 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027
ITALY
TABLE 73: Italy Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 74: Italy Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 75: Italy 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027
TABLE 76: Italy Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 77: Italy Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 78: Italy 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027
UNITED KINGDOM
Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
TABLE 79: UK Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 80: UK Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 81: UK 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027
TABLE 82: UK Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 83: UK Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 84: UK 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027
REST OF EUROPE
TABLE 85: Rest of Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 86: Rest of Europe Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 87: Rest of Europe 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027
TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 89: Rest of Europe Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 90: Rest of Europe 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
TABLE 91: Asia-Pacific Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 92: Asia-Pacific Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 93: Asia-Pacific 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027
TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 95: Asia-Pacific Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 96: Asia-Pacific 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027
REST OF WORLD
TABLE 97: Rest of World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 98: Rest of World Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 99: Rest of World 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027
TABLE 100: Rest of World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 101: Rest of World Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 102: Rest of World 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027
IV. COMPETITION
Total Companies Profiled: 53

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings